开开实业（600272）(600272.SH)发布2025年年度业绩预减公告，预计2025年年度实现归属于母公司所 有者的净利润为1290万元左右，与上年同期相比，将减少2,209.91万元左右，同比减少63.14%左右。 报告期内，公司稳步推进"大健康"战略转型，积极布局新兴业务，并同步开展零售门店升级优化等工 作。由于新兴业务拓展及门店升级优化等项目均需经历一定培育周期，相关效益释放存在滞后性，短期 内既未对经营业绩形成正向贡献，前期投入还对当期利润造成一定影响。与此同时，受行业周期波动及 宏观市场环境综合影响，消费者对高档滋补品消费趋于谨慎，公司顺应市场变化及时调整产品销售结 构，导致经营业绩出现阶段性下滑。 ...

Core Viewpoint - The company reported a revenue increase of 10.95% year-on-year for the first half of 2025, but net profit decreased significantly by 61.94%, indicating challenges in the market despite revenue growth [1] Financial Performance - The company achieved a revenue of 543 million yuan, an increase of 53.62 million yuan compared to the same period last year, reflecting a growth rate of 10.95% [1] - Net profit attributable to shareholders was 11.801 million yuan, down 61.94% year-on-year [1] - The net profit after excluding non-recurring gains and losses was 3.0084 million yuan, a decrease of 8.67% year-on-year [1] - Basic earnings per share were reported at 0.049 yuan [1] Business Segments - The company's "big health" strategic transformation has led to steady growth in the pharmaceutical sector, with the SPD project generating approximately 290 million yuan in revenue, a remarkable year-on-year increase of 52% [1] - The domestic consumption market adjustment has resulted in more rational consumer spending on high-end health products, leading to a decline in sales scale and gross profit for these non-essential items [1] - The apparel segment, while focusing on quality improvement and efficiency, faced challenges due to market conditions and changing consumer sentiment, resulting in decreased sales scale and profitability during the reporting period [1]